Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent EO9

British Journal of Cancer

Volumn 76, Issue 12, 1997, Pages 1596-1603

  Bailey, S M ^a,h   Wyatt, M D ^b,d   Friedlos, F ^c   Hartley, J A ^b   Knox, R J ^c,e   Lewis, A D ^a,f   Workman, P ^a,g  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e CHARING CROSS HOSPITAL   (United Kingdom)

^f HERIOT WATT UNIVERSITY   (United Kingdom)

^g ASTRAZENECA   (United Kingdom)

^h ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Bioreductive agent; DNA damage; DT diaphorase; EO9; Sequence selectivity

Indexed keywords

INDOLOQUINOLINE DERIVATIVE; MITOMYCIN C; PLASMID DNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ALKYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; COLON CARCINOMA; DNA CROSS LINKING; DNA DAMAGE; DNA STRAND BREAKAGE; ENZYME ASSAY; HYPOXIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS;

EID: 0030710552     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.603     Document Type: Article

References (39)

1. Bailey SM, Suggett N, Walton MI and Workman P (1942) Structure-activity relationships for DT-diaphorase reduction of hypoxic cell directed agents: indoloquinones and diaziridinyl benzoquinones. Int J Radiat Oncol Biol Phys 22: 649-653
2. Bailey SM, Lewis AD, Patterson LH, Fisher GR and Workman P (1993) Free radical generation following reduction of EO9: involvement in cytotoxicity. Br J Cancer 67: 8
3. Bailey SM, Wyatt MD, Lewis AD, Hartley JA and Workman P (1994a) Involvement of DT-diaphorase in the DNA cross-linking and sequence selectivity of the novel indoloquinone antitumour agent EO9. Proc Am Assoc Cancer Res 35: 384
4. Bailey SM, Lewis AD and Workman P (1994b) Involvement of NADPH: cytochrome P450 reductase in activation of EO9 to a DNA damaging species. Br J Cancer 69: 57
5. Chen S, Knox R, Lewis AD, Friedlos F, Workman P, Deng PSK, Fung M, Ebenstein D, Wu K and Tsai T (1995) Catalytic properties of NAD(P)H:quinone acceptor oxidoreductase. Study involving mouse, rat, human, and mouse-rat chimeric enzymes. Mol Pharmacol 47: 934-939
6. Collard J, Matthew AM, Double JA and Bibby MC (1995) EO9: relationship between DT-diaphorase and response in vitro and in vivo. Br J Cancer 71: 1199-1203
7. Fitzsimmons SA, Workman P, Grever M, Paull K, Camalier R and Lewis AD (1996) Reductase enzyme expression across the National-Cancer-Institute tumor cell line panel - correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst 88: 259-269
8. Gustafson DL, Beall HD, Bolton EM, Ross D and Waldren CA (1996) Expression of human NAD(P)H:quinone oxidoreductase (DT-diaphorase) in Chinese hamster ovary cells: effect on the toxicity of antitumor quinones. Mol Pharmacol 50: 728-735
9. Hartley JA, Berardini MD and Souhami RL (1991) An agarose gel method for the determination of DNA interstrand crosslinking applicable to the measurement of the rate of total and "second-arm" crosslink reactions. Anal Biochem 193: 131-134
10. Hendriks HR, Pizao PE, Berger DP, Kooistra KL, Bibby MC, Boven E, Dreef-van der Meulen HC, Henrar REC, Fiebig HH, Double JA, Homstra HW, Pinedo HM, Workman P and Schwartsmann G (1993) EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. Eur J Cancer 29A: 897-906
11. Knox RJ, Friedlos F, Jarman M and Roberts JJ (1988) A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridni-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-ly)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells. Biochem Pharmacol 37: 4661-4669
12. Knox RJ, Lydall DA, Friedlos F, Basham C, Rawlings CJ and Roberts JJ (1991) The Walker 256 carcinoma: a cell type inherently sensitive only to those difunctional agents that can form DNA interstrand crosslinks. Mutat Res 255: 227-240
13. Kohn KW, Hartley JA and Mattes WB (1987) Mechanisms of DNA sequence selective alkylation of guanine N-7 positions by nitrogen mustards. Nucleic Acids Res 14: 10531-10549
14. Lee C-S, Hartley JA, Berardini MD, Butler J, Siegel D, Ross D and Gibson NW (1992) Alteration in DNA cross-linking and sequence selectivity of a series of aziridinylbenzoquinones after enzymatic reduction by DT-diaphorase. Biochemistry 31: 3019-3025
15. Maliepaard M, Wolfs A, Groot SE, de Mol NJ and Janssen LHM (1995) Indoloquinone EO9: DNA interstrand cross-linking upon reduction by DT-diaphorase or xanthine oxidase. Br J Cancer 71: 836-839
16. Mattes WB, Hartley JA and Kohn KW (1986) DNA sequence selectivity of guanine N7 alkylation by nitrogen mustards. Nucleic Acid Res 14: 2971-2987
17. Oostveen EA and Speckamp WN (1987) Mitomycin analogues I. Indoloquinones as (potential) bisalkylating agents. Tetrahedron 43: 255-262
18. Paull K, Camalier R, Fitzsimmons SA, Lewis AD, Workman P and Grever M (1994) Correlations of DT-diaphorase expression with cell sensitivity data obtained from the NCI human tumour cell line panel. Proc Am Assoc Cancer Res 35: 369
19. Pavlidis N, Hanauske AR, Gamucci T, Smyth J, Lehnert M, Tevelde A and Lan J (1996) A randomized phase-II study with 2 schedules of the novel indoloquinone-EO9 in non-small-cell lung-cancer - a study of the EORTC early clinical-studies group (ecsg). Ann Oncol 7: 529-531
20. Phillips RM (1996) Bioreductive activation of a series of analogs of 5-aziridinly-3 hydroxymethyl-1-methyl-2-[1h-indole-4,7-dione] prop-β-en-α-ol (E09) by human DT-diaphorase. Biochem Pharmacol 52: 1711-1718
21. Plumb JA and Workman P (1994) Unusually marked hypoxic sensitisation to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity. Int J Cancer 56: 134-139
22. Plumb JA, Gerritsen M, Milroy R, Thomson P and Workman P (1994a) Relative importance of DT-diaphorase and hypoxia in the bioactivation of E09 by human lung tumor cell lines. Int J Radiat Oncol Biol Phys 29: 295-299
23. Plumb JA, Gerritsen M and Workman P (1994b) DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone EO9. Br J Cancer 70: 1136-1143
24. Ponti M, Souhami RL, Fox BW and Hartley, JA (1991) DNA interstrand crosslinking and sequence selectivity of dimethanesulphonates Br J Cancer 63: 743-747
25. Pullman A and Pullman B (1981) Molecular electrostatic potential of the nucleic acids. Quart Rev Biophys 14: 289-380
26. Roberts JJ and Friedlos F (1987) Quantitiative estimation of cisplatin-induced DNA interstrand cross-links and their repair in mammalian cells: relationship to toxicity. Pharmaceut Ther 34: 215-246
27. Roberts JJ, Marchbank T, Kotsaki-Kovatsi VP, Boland MP, Friedlos F and Knox RJ (1989) Caffeine, aminoimidazolecarboxamide and dicoumarol, inhibitors of NAD(P)H dehydrogenase (quinone) (DT-diaphorase), prevent both the cytotoxicity and DNA interstrand crosslinking produced by 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) in Walker Cells. Biochem Pharmacol 38: 4137-4143
28. Robertson N, Haigh A, Adams G and Stratford LJ (1994) Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia. Eur J Cancer 30A: 1013-1019
29. Rosenoer VM, Mitchley BCV, Roe FJC and Connors TA (1966) Walker carcinoma 256 in study of anticancer agents. I. Method for simultaneous assessment of therapeutic value and toxicity. Cancer Res (Cancer Chemotherapy Screening Reports) 26: 937-939
30. Schellens JHM, Planting AST, van Acker BAC, Loos WJ, de Boer-Dennert M, van der Burg MEL, Koier I, Krediet RT, Stoter G and Verweij J (1994) Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug EO9. J Natl Cancer Inst 86: 906-912
31. Siegel D, Gibson NW, Preusch PC and Ross D (1990a) Metabolism of diaziquone by NAD(P)H: (quinone acceptor) oxidoreductase (DT-diaphorase): role in diaziquone-induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res 50: 7293-7300
32. Siegel D, Gibson NW, Preusch PC and Ross D (1990b) Metabolism of mitomycin C by DT-diaphorase: role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res 50: 7483-189
33. Siegel D, Beall H, Senekowitsch C, Kasai M, Arai H, Gibson NW and Ross D (1992) Bioreductive activation of mitomycin C by DT-diaphorase. Biochemistry 31: 7879-7885
34. Smitskamp-Wilms E, Peters GJ, Pinedo HM, van Ark-Otte J and Giaccone G (1994) Chemosensitivity to the indoloquinone EO9 is correlated with DT-diaphorase activity and its gene expression. Biochem Pharmacol 47: 1325-1332
35. Walton MI, Smith PJ and Workman P (1991) The role of NAD(P)H: quinone reductase (EC 16992, DT-diaphorase) in the reductive activation of the novel indoloquinone antitumour agent EO9. Cancer Commun 3: 199-206
36. Walton MI, Suggett N and Workman P (1992a) The role of human and rodent DT-diaphorase in the reductive metabolism of hypoxic cell cytotoxins. Int J Radiat Oncol Biol Phys: 22: 643-648
37. Walton MI, Bibby MC, Double JA, Plumb JA and Workman P (1992a) DT-diaphorase activity correlates with sensitivity to the indoloquinone EO9 in mouse and human colon carcinomas. Eur J Cancer 28A: 1597-1600
38. Wanders J, Pavlidis N, Gamucci T, Huinink WWT, Kirix L, Wolff I and Verweij J (1995) Phase-II studies with EO9 in breast, colorectal, gastric, pancreatic and NSCLC. Eur J Cancer 31: 565-565
39. Workman P (1994) Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase. Oncol Res 6: 461-475